Product image of Influvac Tetra (B/Phuket/3073/2013-Like Virus (B/Phuket/3073/2013, Wild Type), Influenza Virus B/Austria/1359417/202) supplied by GNH India

Influvac Tetra

Active Ingredient:
B/Phuket/3073/2013-Like Virus (B/Phuket/3073/2013, Wild Type), Influenza Virus B/Austria/1359417/202
Origin:
EU

Influvac Tetra (B/Phuket/3073/2013-Like Virus (B/Phuket/3073/2013, Wild Type), Influenza Virus B/Austria/1359417/202)

influenza virus vaccine, quadrivalent, the active ingredient in Influvac Tetra, is a vaccine presented as an injectable solution for intramuscular, subcutaneous use. It induces active immunity to prevent influenza infection caused by the four virus strains included in the formulation, targeting individuals at risk of seasonal flu.

GNH India supplies Influvac Tetra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved products to meet global immunization needs.

Manufacturer / TM Owner

Viatris Hrvatska D.O.O.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Influvac Tetra is a quadrivalent influenza vaccine used for active immunization against seasonal influenza.

  • Seasonal influenza (any age): Provides protection against infection by the four influenza virus strains included in the vaccine.
  • Elderly population (≥65 years): Reduces risk of severe influenza and related complications.
  • Individuals with chronic medical conditions: Lowers incidence of influenza‑related morbidity.

How It Works

  • Influvac Tetra contains inactivated influenza virus strains that present hemagglutinin and neuraminidase antigens to the immune system. Upon intramuscular or subcutaneous injection, antigen‑presenting cells process these proteins, stimulating B‑cell production of strain‑specific antibodies and generating memory T‑cell responses, thereby establishing active immunity against the targeted influenza viruses.

Side Effects

Common Side Effects

  • Injection site pain: mild to moderate discomfort at the injection site.
  • Redness or swelling: localized erythema or edema.
  • Low‑grade fever: transient temperature rise within 24‑48 hours.
  • Headache: mild headache often resolves spontaneously.
  • Myalgia: muscle aches that are usually short‑lived.
  • Fatigue: temporary feeling of tiredness.

Serious or Rare Side Effects

  • Anaphylaxis: severe allergic reaction requiring immediate medical attention.
  • Guillain‑Barré syndrome: rare neurological disorder with progressive weakness.
  • Severe allergic reaction: urticaria, angioedema, or respiratory distress.
  • Seizures: uncommon neurologic event, especially in febrile children.
  • High fever: temperature >40 °C persisting beyond 48 hours.
  • Thrombocytopenia: rare drop in platelet count.

Precautions & Warnings

Before administration, consider the following precautions:

  • Allergy to vaccine components: avoid if known hypersensitivity to any ingredient.
  • History of severe allergic reaction to previous influenza vaccines: consult a specialist.
  • Acute febrile illness: defer vaccination until recovery.
  • Immunocompromised patients: monitor immune response and consider alternative strategies.
  • Pregnancy and breastfeeding: discuss risk‑benefit with healthcare provider.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Vaccination may be influenced by other medical products. Monitor accordingly.

Major Interactions (Avoid)

  • Concurrent administration of immunoglobulins or blood products: may reduce vaccine efficacy.
  • Live attenuated vaccines within 4 weeks: potential interference with immune response.

Moderate Interactions (Monitor Closely)

  • Prophylactic antipyretics (acetaminophen, ibuprofen): may blunt antibody production.
  • Immunosuppressive therapy: assess serologic response after vaccination.
  • Allergy medications (antihistamines): generally safe but monitor for atypical reactions.

Frequently Asked Questions

Influvac Tetra is a quadrivalent influenza vaccine indicated for active immunization to prevent seasonal influenza caused by the four virus strains contained in the formulation. It is administered to individuals who need protection against circulating flu viruses each year.

The vaccine contains inactivated virus particles that display hemagglutinin and neuraminidase antigens. After injection, the immune system recognizes these antigens, prompting B‑cells to produce specific antibodies and generating memory T‑cells, which together provide protection against infection by the matching influenza strains.

The prescribed dose of Influvac Tetra is determined by the treating healthcare professional based on age, health status, and local immunization guidelines. The prescriber decides the exact volume and schedule appropriate for each patient.

The safety of Influvac Tetra in pregnancy and lactation has not been definitively established. Healthcare providers should evaluate the potential benefits and risks for each individual, and vaccination may be considered when the expected benefit outweighs any uncertain risk.

To place an order, submit an enquiry on the Influvac Tetra product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and necessary import documentation.

Influvac Tetra is a quadrivalent, inactivated vaccine covering two influenza A subtypes and two B lineages, offering broader protection than trivalent formulations that contain only one B strain. Its safety profile and immunogenicity are comparable to other licensed quadrivalent vaccines, but specific comparative data depend on the reference product.

Influvac Tetra must be stored refrigerated at 2‑8 °C. Keep the vials in the original packaging, protect them from light, and avoid freezing or shaking. Do not use the product if it has been exposed to temperatures outside this range.

The vaccine is supplied as an injectable solution and is given by a trained healthcare professional via intramuscular or subcutaneous injection, typically into the deltoid muscle of the upper arm. The injection site should be cleaned with an antiseptic before administration.

Serious adverse events, though rare, include anaphylaxis, Guillain‑Barré syndrome, severe allergic reactions, high‑grade fever, seizures, and thrombocytopenia. Immediate medical attention is required if any of these symptoms develop after vaccination.

Individuals with a known severe allergy to any component of the vaccine, or who have experienced a severe allergic reaction to a previous dose of an influenza vaccine, should not receive Influvac Tetra. Persons with acute febrile illness should defer vaccination until recovery.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing B/Phuket/3073/2013-Like Virus (B/Phuket/3073/2013, Wild Type), Influenza Virus B/Austria/1359417/202

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT